This article is more than 5 years old. Information may no longer be current.
Otezla effective in patients with palmoplantar psoriasis
Click Here to Manage Email Alerts
Patients in this study with moderate-to-severe palmoplantar psoriasis showed clinical improvement at 16 weeks after treatment with Otezla compared with placebo, according to recent data.
“[Otezla (apremilast, Celgene)] was well tolerated and demonstrated efficacy in patients with moderate-to-severe palmoplantar psoriasis,” Robert Bissonnette, MD, from Innovaderm Research Inc. in Montreal, and colleagues wrote. “Further studies, including studies in patients with extensive and severe palmoplantar psoriasis, are warranted to confirm these findings.”
Bissonnette and colleagues performed an ad hoc analysis of data from a phase 2b and the phase 3 ESTEEM trials. This analysis included a subset of patients with moderate-to-severe plaque psoriasis and active palmoplantar psoriasis, defined as a baseline Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of 1 or greater. Patients had been randomly assigned to apremilast 30 mg or placebo.
They found that 48% of patients with moderate-to-severe palmoplantar psoriasis (PPPGA score 3) who received apremilast achieved a PPPGA score of 0 of 1 at 16 weeks), vs. 27% of patients who received placebo (P = .021). Among patients with a PPPGA score of 1 or higher at baseline, 46% of patients in the apremilast group achieved a score of 0 within 16 weeks compared with 25% of patients in the placebo group (P < .001). Overall, 59% of apremilast patients showed a 1-point improvement and had PPPGA scores of 0 or 1 compared with 39% of patients in the placebo group (P < .001). – by Jeff Craven
Disclosure: Bissonnette is on the advisory boards and has received grants from AbbVie, Amgen, Celgene Corporation, Eli Lilly, Galderma Laboratories, Incyte, Janssen, Kineta, LEO Pharma US, Merck, Novartis Pharmaceuticals, Pfizer and Tribute. Please see the full study for a complete list of disclosures.
Click Here to Manage Email Alerts